Aids Healthcare Foundation
Based in CA
AI Overview
With $1.7M in lobbying spend across 29 quarterly filings, Aids Healthcare Foundation is a significant lobbying presence. Their lobbying covers 7 issue areas. Active from 2018 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $240K |
| 2019 | $120K |
| 2020 | $240K |
| 2021 | $240K |
| 2022 | $240K |
| 2023 | $240K |
| 2024 | $240K |
| 2025 | $180K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: MED, Health Issues, Banking, Consumer Issues, Housing and 2 more
Department of Labor, Health, Human Services, and Education, and Related Agencies Appropriations Act, FY 2018 - Support funding for medical treatments for HIV positive patients.
340B Drug Pricing Program.
340B Drug Pricing Program
Department of Labor, Health, Human Services, and Education, and Related Agencies.....Appropriations ACT, FY2018 - Support Funding for medical treatments for HIV positive patients.
Advocacy Regarding Middle Income Country Designation
To Address Pharmacy DIR fees in next CoVid19 package.
H.R.1034 the Phair Drug Pricing Act of 2019.
S640 the Phair Drug Pricing Act of 2019.
S2543 Grassley/Wyden's Prescription Drug Pricing Reduction Act of 2019
To Address Pharmacy DIR fees in next CoVid19 package.
Add DIR report language to the Labor-HHS Appropriations Bill 2021
S2543 Grassley/Wyden's Prescription Drug Pricing Reduction Act of 2019
To Address Pharmacy DIR fees in next CoVid19 package.
H.R.1034/S.640, The Phair Pricing Act of 2019
H.R. 7838- To provide for certain temporary waivers with respect to the 340B drug discount program due to COVID-19 public health emergency, and for other purposes.
S.4160- A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes.
S.2543 Grassley/Wyden's Prescription Drug Pricing Reduction Act of 2019
Executive Order on insulin and Epi-Pen
Showing 8 of 20 unique descriptions from filings.
Related Analysis
Related Investigations
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.